Gabapentin Tablet
Product Images NDC 69097-812

The given text provides a table with recommended dosages of the drug Gabapentin that are based on the patient's renal function, measured by creatinine clearance. The table displays the total daily dose range for patients with different levels of renal function. TID, BID, and QID denote dosing frequency for three times a day, two times a day, and a single daily dose, respectively. For patients undergoing hemodialysis, the table recommends maintenance doses based on creatinine clearance estimates and a supplemental post-hemodialysis dose to be administered after each 4 hours of hemodialysis.*

This appears to be a formula for calculating the creatinine clearance (CLCy) in patients based on their weight and serum creatinine levels. The formula takes into account the patient's gender by multiplying by 0.85 for female patients. However, it is not clear what the units of measurement are, as some of the text is unreadable.*

This is a table presenting the risk of events (not specified in the text) associated with antiepileptic drugs compared to a placebo. The data is presented by indication (epilepsy, psychiatric, and other) and shows the number of patients with events per 1000 patients, as well as the relative risk and risk difference between drug patients and placebo patients. There is not enough information to determine what the events referred to in the table are.*

The text is showing the results of controlled PHN studies and the proportion of responders (patients with more than 50% reduction in pain score) at endpoint. There are two studies mentioned, but only one shows a proportion of 34% of responders. The text also shows statistical significance (p<0.001). The last part of the text seems to mention some dosage information, although it is not clear what it pertains to.*

NDC 69097-812-07, Rx Only. Gabapentin is a medicine available in the form of USP tablets. Each tablet contains 600mg of gabapentin. The medication guide must be provided to each patient by the pharmacist. Read the package insert for full prescribing information, dosage, and usage instructions. The tablets should be stored within the USP-controlled room temperature of 20°-25°C. The medicine should be dispensed in a tight container with a child-resistant closure. The manufacturer is InvaGen Pharmaceuticals, Inc. (a subsidiary of Cipla Ltd.), and it is manufactured for Cipla USA, Inc. The also picked up some symbols and characters that are not readable.*

Each tablet of NDC 69097-812-07 contains 600 mg of gabapentin, USP. This medication is for prescription use only and comes with a medication guide insert for full prescribing information. It is recommended to dispense in a tight container with a child-resistant closure as defined in the USP. Manufactured by Ascent Pharmaceuticals, Inc. and distributed by Cipla USA, Inc. in Warren, NJ. Dosage and use should be determined by a healthcare professional.*

Gabapentin is a medicine provided in tablet form by Cipla. Each tablet contains 800 mg of gabapentin, USP. The medication guide must be dispensed separately to each patient. The tablets should be stored in USP-controlled room temperature between 20°C-25°C (68°F-77°F). The full prescribing information can be found in the package insert. The tablets should be dispensed in a tight container with a child-resistant closure. They are manufactured by InvaGen Pharmaceuticals, Inc, which is a subsidiary of Cipla Ltd., and are made for Cipla USA, Inc. Unfortunately, there is some unclear text in the document.*

This is a prescription drug called gabapentin, with NDC 69097-811-07 and manufactured by Ascent Pharmaceuticals Inc. Dosage and usage directions can be found in the package insert. It contains 800mg of gabapentin, USP and comes in a container with 100 tablets. The medication guide should be dispensed separately to each patient by the pharmacist. It should be stored at 20°-25°C (68°-77°F). Manufactured for Cipla USA, Inc. with a child-resistant closure. The rest of the text is illegible due to errors.*